All In MedTech

Device Trial Radar · NCT03041467

IN.PACT™ AV Access IDE Study

Randomized Study of IN.PACT™ AV Access Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon vs. Standard PTA for the Treatment of Obstructive Lesions in the Native Arteriovenous Dialysis Fistulae (AVF)

Last checked: Nov 20, 2026Latest source record: May 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

330

Actual

Start

Apr 25, 2017

Primary completion

Dec 6, 2018

Study completion May 5, 2023

Sponsor

Lead sponsor
Medtronic EndovascularPublic (MDT)
Sponsor type
Industry
First posted
Feb 2, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and efficacy of the IN.PACT™ AV Access Drug Coated Balloon (DCB) compared to percutaneous transluminal angioplasty (PTA) for treatment of subjects presenting with de novo or non-stented restenotic obstructive lesion of native arteriovenous dialysis fistulae (AVF) in the upper extremity.

Conditions

  • Arteriovenous Fistula Stenosis
  • Arteriovenous Fistula Occlusion
  • Arteriovenous Fistula
  • Fistula

Interventions

  • IN.PACT AV DCBDevice

    IN.PACT™ AV Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon

  • Standard Balloon AngioplastyDevice

    Standard PTA Balloon

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Target Lesion Primary Patency Rate Through 6 MonthsTime frame: 6 Months Post-Procedure
  2. Primary Safety Endpoint - Serious Adverse Event RateTime frame: 30 days post procedure

Locations

29 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham (UAB) Hospital

    Birmingham, Alabama

  • SKI Vascular Center

    Tempe, Arizona

  • Capital Nephrology Medical Group

    Sacramento, California

26 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.